Drug eluting stents may not be the answer for myocardial bridges

Int J Cardiol. 2007 Apr 25;117(2):e76-8. doi: 10.1016/j.ijcard.2006.11.158. Epub 2007 Feb 27.

Abstract

Although medical treatment is the first-line therapy for myocardial bridges, in some cases revascularization may be required. Percutaneous intervention with bare metal stents is associated with a high restenosis rate. It has been speculated that drug eluting stents might be useful in this setting, although data are limited. We present a patient who suffered multifocal in-stent restenosis after a paclitaxel stent in a myocardial bridge.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Angina, Unstable / therapy
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Coronary Restenosis / etiology*
  • Coronary Vessel Anomalies / therapy*
  • Drug Delivery Systems
  • Humans
  • Male
  • Middle Aged
  • Paclitaxel / adverse effects*
  • Stents / adverse effects*

Substances

  • Antineoplastic Agents, Phytogenic
  • Paclitaxel